Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Influence of CCR5Δ32 gene mutation on interferon-beta treatment response in multiple sclerosis (CROSBI ID 629916)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Ristić, Smiljana ; Mikulčić, Mateja ; Starčević Čizmarević, Nada ; Lovrečić, Luca ; Lavtar, Polona ; Sepčić, Juraj ; Šega Jazbec, Saša ; Kapović, Miljenko ; Peterlin, Borut Influence of CCR5Δ32 gene mutation on interferon-beta treatment response in multiple sclerosis // Book of abstracts, 11th Balkan Congress of Human Genetics. 2015

Podaci o odgovornosti

Ristić, Smiljana ; Mikulčić, Mateja ; Starčević Čizmarević, Nada ; Lovrečić, Luca ; Lavtar, Polona ; Sepčić, Juraj ; Šega Jazbec, Saša ; Kapović, Miljenko ; Peterlin, Borut

engleski

Influence of CCR5Δ32 gene mutation on interferon-beta treatment response in multiple sclerosis

Interferon beta (IFN-β) is widely used as the first-line disease-modifying treatment for multiple sclerosis (MS). However, response to IFN-β is largely heterogeneous, and a significant number of MS patients (20-50%) continue to experience clinical and MRI disease activity despite treatment. Identification of biomarkers that predict responsiveness to IFN-β is important to define therapy strategies. The aim of this study was to analyze the association of CCR5Δ32 mutation with presence or absence of clinical response to IFN-β treatment in Croatian and Slovenian MS patients. We genotyped 161 IFN-β-treated patients with relapsing-remitting or secondary-progres¬sive MS. Based on clinical criteria for efficiency of MS treatment, patients were classified as responders, Rs (N=93) and nonresponders, NRs (N=68). 32 bp deletion in the CCR5 gene was detected using one-step PCR. No significant differences between Rs and NRs in CCR5 allele (p=0, 826) and genotype (p=0, 823) frequencies were observed. Also, in stratifying MS patients by gender or disease course, no significant differences in allele and genotype distributions between Rs and NRs were found. Our results indicate that the carriage of CCR5Δ32 mutation was not associated with IFN-β treatment response in Croatian and Slovenian MS patients.

Multiple sclerosis; CCR5 Δ32; Interferon-β; Treatment responsiveness

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2015.

objavljeno

Podaci o matičnoj publikaciji

Book of abstracts, 11th Balkan Congress of Human Genetics

Podaci o skupu

11th Balkan Congress of Human Genetics (11th BCHG)

poster

17.09.2015-20.09.2015

Beograd, Srbija

Povezanost rada

nije evidentirano